1. DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR). (June 2017) Authors: Lentzsch, S.; Weisel, K.; Mateos, M.V.; Hungria, V.; Munder, M.; Nooka, A.; Mark, T.; Quach, H.; Scott, E.; Lee, J.; Sonneveld, P.; Casneuf, T.; Chiu, C.; Qin, X.; Amin, H.; Thiyagarajah, P.; Schecter, J.; Qi, M.; Spencer, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID‐19 in a tertiary center – A monocentric analysis. (15th February 2023) Authors: Schaefers, C.; Paulsen, F.‐O.; Frenzel, C.; Weisel, K.; Bokemeyer, C.; Seidel, C. Journal: British journal of haematology Issue: Volume 201:Number 2(2023) Page Start: 222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LABEL DOSE ESCALATION STUDY. (23rd June 2022) Authors: van de Donk, N. W.; Guo, S.; Shi, L.; Lord-Bessen, J.; Tang, D.; Karlin, L.; Weisel, K.; Ramasamy, K.; Abad, P. C.; Amin, A.; Amin, S.; Lonial, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P890: THE OUTCOME OF SECOND PRIMARY MALIGNANCIES DEVELOPING IN MM PATIENTS. (23rd June 2022) Authors: Avivi, I.; H vesole, D.; Dávila Valls, J.; Usnarska-Zubkiewicz, L.; Milunovic, V.; Bogumiła Osękowska, B. B.; Kopińska, A.; Gentile, M.; MARTÍNEZ, B. P.; Robak, P.; crusoe, E.; LUIS GERARDO, R.; Gajewska, M.; Gergely, V.; Delforge, M.; Cohen, Y.; Alessandro, G.; peña, C.; Shustik, C.; Mikala, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 782 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY. (23rd June 2022) Authors: Oriol, A.; Dimopoulos, M.; Schjesvold, F.; Beksac, M.; Yagci, M.; Larocca, A.; Guo, S.; Mu, Y.; Hong, K.; Dhanasiri, S.; Richardson, P.; Weisel, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 792 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL. (23rd June 2022) Authors: Leypoldt, L.; Gavriatopoulou, M.; Besemer, B.; Salwender, H.; Raab, M.-S.; Nogai, A.; Khandanpour, C.; Runde, V.; Zago, M.; Martus, P.; Goldschmidt, H.; Bokemeyer, C.; Dimopoulos, M.; Weisel, K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 816 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY. (23rd June 2022) Authors: Spencer, A.; Moreau, P.; Mateos, M.-V.; Goldschmidt, H.; Suzuki, K.; Levin, M.-D.; Sonneveld, P.; Yoon, S.-S.; Usmani, S. Z.; Weisel, K.; Reece, D.; Ahmadi, T.; Pei, H.; Garvin Mayo, W.; Gai, X.; Carey, J.; Carson, R.; Dimopoulos, M. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 823 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY. (23rd June 2022) Authors: Einsele, H.; Moreau, P.; Delforge, M.; van de Donk, N. W.; Ghilotti, F.; Diels, J.; Elsada, A.; Strulev, V.; Pei, L.; Kobos, R.; Smit, J.; Slavcev, M.; Weisel, K.; Mateos, M.-V. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 825 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. (23rd June 2022) Authors: Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Borgsten, F.; Usmani, S. Z. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 826 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY. (23rd June 2022) Authors: Suvannasankha, A.; Bahlis, N.; Trudel, S.; Weisel, K.; Koenecke, C.; Oriol, A.; Voorhees, P. M.; Alonso, A. A.; Callander, N. S.; Mateos Manteca, M. V.; Reddy, N.; Hakim, S.; Patel, N.; Williams, D.; Jewell, R. C.; Zhou, X.; Gupta, I.; Nooka, A. K. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗